Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study)

Basit Öğe Kaydı
dc.contributor.authorYilmaz Ciftdogan, Dilek
dc.contributor.authorEkemen Keles, Yildiz
dc.contributor.authorKarbuz, Adem
dc.contributor.authorCetin, Benhur Sirvan
dc.contributor.authorElmas Bozdemir, Sefika
dc.contributor.authorKepenekli Kadayifci, Eda
dc.contributor.authorMetin Akcan, Ozge
dc.date.accessioned2024-02-23T14:24:31Z
dc.date.available2024-02-23T14:24:31Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractAim Multisystem inflammatory syndrome in children (MIS-C) may cause shock and even death in children. The aim of this study is to describe the clinical features, laboratory characteristics and outcome of children diagnosed with MIS-C in 25 different hospitals in Turkey. Methods The retrospective study was conducted between 8 April and 28 October 2020 in 25 different hospitals from 17 cities. Data were collected from patients' medical records using a standardised form. Clinical and laboratory characteristics and outcomes according to different age groups, gender and body mass index percentiles were compared using multivariate logistic regression analysis. Results The study comprised 101 patients, median age 7 years (interquartile range (IQR) 4.6-9.3); 51 (50.5%) were boys. Reverse-transcriptase polymerase chain reaction (PCR) assay was positive in 21/100 (21%) patients; 62/83 (74.6%) patients had positive serology for SARS-CoV-2. The predominant complaints were fever (100%), fatigue (n = 90, 89.1%), and gastrointestinal symptoms (n = 81, 80.2%). Serum C-reactive protein (in 101 patients, median 165 mg/L; range 112-228), erythrocyte sedimentation rate (73/84, median 53 mm/s; IQR 30-84) and procalcitonin levels (86/89, median 5 mu g/L; IQR 0.58-20.2) were elevated. Thirty-eight patients (37.6%) required admission to intensive care. Kawasaki disease (KD) was diagnosed in 70 (69.3%) patients, 40 of whom had classical KD. Most patients were treated with intravenous immunoglobulin (n = 92, 91%) and glucocorticoids (n = 59, 58.4%). Seven patients (6.9%) died. Conclusion The clinical spectrum of MIS-C is broad, but clinicians should consider MIS-C in the differential diagnosis when persistent fever, fatigue and gastrointestinal symptoms are prominent. Most patients diagnosed with MIS-C were previously healthy. Immunomodulatory treatment and supportive intensive care are important in the management of cases with MIS-C. Glucocorticoids and intravenous immunoglobulins are the most common immunomodulatory treatment options for MIS-C. Prompt diagnosis and prompt treatment are essential for optimal management.en_US
dc.identifier.doi10.1111/jpc.15913
dc.identifier.endpage1078en_US
dc.identifier.issn1034-4810
dc.identifier.issn1440-1754
dc.identifier.issue6en_US
dc.identifier.pmid35199895en_US
dc.identifier.scopus2-s2.0-85125111465en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1069en_US
dc.identifier.urihttps://doi.org/10.1111/jpc.15913
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13986
dc.identifier.volume58en_US
dc.identifier.wosWOS:000760265600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Paediatrics And Child Healthen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChilden_US
dc.subjectCovid-19en_US
dc.subjectKawasaki Diseaseen_US
dc.subjectMis-Cen_US
dc.subjectShocken_US
dc.titleMultisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu